AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35276991 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (group A)
Number of subjects: 664
Study 35276991 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 664
Study 35125253 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities that HEAL (CTH) intervention implementing evidence-based practices (EBPs) to reduce opioid overdose deaths
Number of subjects: 382
Study 35125253 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 382
Study 34195102 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot supplement
Number of subjects: 12
Study 34195102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 34195102 — intervention group
Group type: COMPARATOR
Intervention: Water intake
Number of subjects: 12
Study 35110416 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus anthracycline or non-anthracycline chemotherapy
Number of subjects: 662
Study 35110416 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based therapy
Number of subjects: 662
Study 35110416 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-trastuzumab treated patients)
Number of subjects: 662
Study 33794441 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 0
Study 33794441 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice
Number of subjects: 0
Study 36219614 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma microRNA-221-3p levels at 1 day before and 7 days after surgery
Number of subjects: 0
Study 36219614 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma microRNA-221-3p levels at 7 days after surgery
Number of subjects: 0
Study 36219614 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma microRNA-221-3p at postoperative 7 days
Number of subjects: 0
Study 36219614 — intervention group
Group type: COMPARATOR
Intervention: POCD diagnosis
Number of subjects: 0
Study 33524646 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 45
Study 33524646 — intervention group
Group type: COMPARATOR
Intervention: Conventional saline dressings
Number of subjects: 45
Study 33817779 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis (AD)
Number of subjects: 10788
Study 35870332 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil massage
Number of subjects: 42
Study 35870332 — intervention group
Group type: COMPARATOR
Intervention: Placebo massage
Number of subjects: 42
Study 34518245 — intervention group
Group type: EXPERIMENTAL
Intervention: web‐based connected device (activity tracker, smartphone application, website)
Number of subjects: 432
Study 34518245 — intervention group
Group type: EXPERIMENTAL
Intervention: therapeutic patient education (one educational diagnosis, two collective educational sessions, one evaluation)
Number of subjects: 432
Study 34518245 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of both interventions
Number of subjects: 432
Study 34518245 — intervention group
Group type: COMPARATOR
Intervention: control (usual care)
Number of subjects: 432
Study 37078430 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 30
Study 37078430 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control group
Number of subjects: 30
Study 34898896 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone 30 mg/day
Number of subjects: 200
Study 34898896 — intervention group
Group type: COMPARATOR
Intervention: Vaginal progesterone 600 mg/day
Number of subjects: 200
Study 33929938 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to 10 adaptive learning modules during the dermatology rotation
Number of subjects: 0
Study 33929938 — intervention group
Group type: COMPARATOR
Intervention: No access to adaptive learning modules during the dermatology rotation
Number of subjects: 0
Study 33929938 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 0
Study 32427813 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized education session on the Walter Reed HO classification system followed by 2 grading sessions
Number of subjects: 100
Study 36841463 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52 mg IUD
Number of subjects: 318
Study 36841463 — intervention group
Group type: COMPARATOR
Intervention: Copper 380 mm2 IUD
Number of subjects: 318
Study 36841463 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel 19.5 mg IUD
Number of subjects: 318
Study 33443874 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention
Number of subjects: 83
Study 32745964 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 3265
Study 36123938 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality nursing (n = 192)
Number of subjects: 372
Study 36123938 — intervention group
Group type: COMPARATOR
Intervention: Normal nursing (n = 180)
Number of subjects: 372
Study 33856324 — intervention group
Group type: COMPARATOR
Intervention: No difficult airway characteristics
Number of subjects: 1513
Study 33856324 — intervention group
Group type: EXPERIMENTAL
Intervention: One or more anatomically difficult airway characteristics
Number of subjects: 1513
Study 33856324 — intervention group
Group type: EXPERIMENTAL
Intervention: One or more physiologically difficult airway characteristics
Number of subjects: 1513
Study 33856324 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anatomically and physiologically difficult airway characteristics
Number of subjects: 1513
Study 33856324 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomically difficult airway characteristics
Number of subjects: 1513
Study 33856324 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologically difficult airway characteristics
Number of subjects: 1513
Study 35213459 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal lavage using 10 L normal saline
Number of subjects: 193
Study 35213459 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal lavage using distilled water
Number of subjects: 193
Study 35213459 — intervention group
Group type: COMPARATOR
Intervention: Control group with no lavage
Number of subjects: 193
Study 35980169 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for asymptomatic bacteriuria (AB)
Number of subjects: 80
Study 35980169 — intervention group
Group type: COMPARATOR
Intervention: No treatment for asymptomatic bacteriuria (AB)
Number of subjects: 80
Study 33940954 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 3941
Study 33940954 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (Control)
Number of subjects: 3941
Study 33940954 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ≥50% carotid stenosis
Number of subjects: 3941
Study 33110037 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased levels of cognitive complaints
Number of subjects: 44
Study 33110037 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased depressive symptoms and somatic complaints
Number of subjects: 44
Study 33110037 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory tasks performance
Number of subjects: 44
Study 36401652 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine eyedrops, administered once nightly for 1 year
Number of subjects: 105
Study 36401652 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 105
Study 36401652 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine eyedrops, administered for 6 months after crossover
Number of subjects: 105
Study 36401652 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine eyedrops
Number of subjects: 105
Study 33658764 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0mg/kg
Number of subjects: 80
Study 33658764 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 40 µg/kg
Number of subjects: 80
Study 36051482 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on the theory of planned behavior (TPB) consisting of five sessions of 45‐60 minutes
Number of subjects: 98
Study 36051482 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 98
Study 33744202 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prescriptions written by general practitioners (GPs)
Number of subjects: 180
Study 33744202 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prescriptions written by nurses
Number of subjects: 180
Study 33744202 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prescriptions for skin and soft-tissue infection
Number of subjects: 180
Study 33744202 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prescriptions for lower respiratory-tract infection
Number of subjects: 180
Study 33744202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, amoxicillin-clavulanate, and cefalexin
Number of subjects: 180
Study 33744202 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall antimicrobial prescribing in remote clinics
Number of subjects: 180
Study 35251398 — intervention group
Group type: COMPARATOR
Intervention: Paravertebral nerve block (PVB)
Number of subjects: 74
Study 35251398 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial serratus anterior plane block (SSPB)
Number of subjects: 74
Study 33087111 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg daily orally at 21:00 for 28 days
Number of subjects: 60
Study 33087111 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily orally at 21:00 for 28 days
Number of subjects: 60
Study 34406549 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental simulation of future waterpipe tobacco smoking (WTS)
Number of subjects: 1000
Study 34406549 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive or no valence mental simulation of WTS
Number of subjects: 1000
Study 34406549 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mental simulation of WTS
Number of subjects: 1000
Study 34406549 — intervention group
Group type: COMPARATOR
Intervention: Mental simulation of WTS
Number of subjects: 1000
Study 33879902 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic nomogram model based on immune inflammation-related markers
Number of subjects: 200
Study 33879902 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic nomogram model based on peripheral blood parameters
Number of subjects: 200
Study 33879902 — intervention group
Group type: COMPARATOR
Intervention: Peripheral blood parameters
Number of subjects: 200
Study 33879902 — intervention group
Group type: COMPARATOR
Intervention: Non-muscle-invasive ureteral urothelial carcinoma
Number of subjects: 200
Study 33879902 — intervention group
Group type: COMPARATOR
Intervention: Muscle-invasive ureteral urothelial carcinoma
Number of subjects: 200
Study 35667164 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care consultation within 72 hours of hospitalization
Number of subjects: 22
Study 35667164 — intervention group
Group type: COMPARATOR
Intervention: Standard intensive care
Number of subjects: 22
Study 32131070 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide prevention nursing competency program (120 minutes, twice a week for 3 weeks)
Number of subjects: 66
Study 32131070 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide prevention nursing competency program
Number of subjects: 66
Study 35272560 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral buckle
Number of subjects: 16
Study 35272560 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 16
Study 35272560 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined scleral buckle and vitrectomy
Number of subjects: 16
Study 32769757 — intervention group
Group type: EXPERIMENTAL
Intervention: Fezolinetant 15, 30, 60, or 90 mg BID or 30, 60, or 120 mg QD
Number of subjects: 356
Study 32769757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 32769757 — intervention group
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Number of subjects: 356
Study 32221809 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous needle aspiration (PNA)
Number of subjects: 100
Study 32221809 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous catheter drainage (PCD)
Number of subjects: 100
Study 35927616 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized outpatient follow-up for one year post-discharge
Number of subjects: 173
Study 35927616 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 173
Study 32407654 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg‐1)
Number of subjects: 19
Study 32407654 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 19
Study 35029612 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten Friendly™ bread (3 g)
Number of subjects: 48
Study 35029612 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten Friendly™ bread (6 g)
Number of subjects: 48
Study 35029612 — intervention group
Group type: COMPARATOR
Intervention: Gluten Friendly™ bread (0 g)
Number of subjects: 48
Study 33818140 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 943
Study 33818140 — intervention group
Group type: COMPARATOR
Intervention: Apalutamide
Number of subjects: 943
Study 33818140 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 943
Study 32075507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (bolus 1.5 mg kg−1 followed by 1.5 mg kg−1 h−1 for 3 hours)
Number of subjects: 0
Study 32075507 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin without lidocaine
Number of subjects: 0
Study 36115968 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 L PEG + LB
Number of subjects: 140
Study 36115968 — intervention group
Group type: COMPARATOR
Intervention: 4 L PEG
Number of subjects: 140
Study 33887208 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 sclamp vaccine at 5 μg
Number of subjects: 120
Study 33887208 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 sclamp vaccine at 15 μg
Number of subjects: 120
Study 33887208 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 sclamp vaccine at 45 μg (two doses)
Number of subjects: 120
Study 33887208 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 sclamp vaccine at 45 μg (single dose)
Number of subjects: 120
Study 33887208 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of sclamp vaccine at any concentration
Number of subjects: 120
Study 33887208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 33887208 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 sclamp vaccine at any dose
Number of subjects: 120
Study 33169704 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) insufflation
Number of subjects: 204
Study 33169704 — intervention group
Group type: COMPARATOR
Intervention: Room air (RA) insufflation
Number of subjects: 204
Study 33169704 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation in patients with inflammatory bowel disease (IBD)
Number of subjects: 204
Study 33169704 — intervention group
Group type: EXPERIMENTAL
Intervention: Other contributing factors to pain sensation
Number of subjects: 204
Study 36472683 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading by housings (group A)
Number of subjects: 79
Study 36472683 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading (group B)
Number of subjects: 79
Study 36472683 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular MIs
Number of subjects: 79
Study 36472683 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary MIs
Number of subjects: 79
Study 34330881 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge nurse phone call
Number of subjects: 0
Study 34330881 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital discharge processes
Number of subjects: 0
Study 35879528 — intervention group
Group type: COMPARATOR
Intervention: Control low-fat diet
Number of subjects: 70
Study 34851202 — intervention group
Group type: EXPERIMENTAL
Intervention: TELECARE (remote bio-parameters telemonitoring system)
Number of subjects: 510
Study 34851202 — intervention group
Group type: EXPERIMENTAL
Intervention: TELECARE
Number of subjects: 510
Study 35659655 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) applied on days 0, 3, 7, 14, and every 2 weeks thereafter using a Diode laser with a wavelength of 980 nm.
Number of subjects: 20
Study 35659655 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) applied every 3 weeks using a Diode laser with a wavelength of 980 nm.
Number of subjects: 20
Study 35659655 — intervention group
Group type: COMPARATOR
Intervention: Control (no PBM treatment).
Number of subjects: 20
Study 32570678 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence conversational agent technologies and behavioral activation therapy techniques
Number of subjects: 0
Study 32570678 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35184228 — intervention group
Group type: EXPERIMENTAL
Intervention: JUUL2 prototype 18 mg/mL nicotine
Number of subjects: 40
Study 35184228 — intervention group
Group type: EXPERIMENTAL
Intervention: JUUL2 prototype 40 mg/mL
Number of subjects: 40
Study 35184228 — intervention group
Group type: EXPERIMENTAL
Intervention: JUUL
Number of subjects: 40
Study 35184228 — intervention group
Group type: COMPARATOR
Intervention: IQOS 18 mg/g
Number of subjects: 40
Study 35184228 — intervention group
Group type: COMPARATOR
Intervention: Combustible cigarettes
Number of subjects: 40
Study 35184228 — intervention group
Group type: COMPARATOR
Intervention: JUUL 59 mg/mL
Number of subjects: 40
Study 35811184 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based fruit and vegetable promotion program for 24 weeks
Number of subjects: 6
Study 32446298 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment
Number of subjects: 3570
Study 32446298 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3570
Study 36164960 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked condition (smiling)
Number of subjects: 950
Study 36164960 — intervention group
Group type: COMPARATOR
Intervention: Unmasked condition (smiling)
Number of subjects: 950
Study 36164960 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person evaluation
Number of subjects: 950
Study 36164960 — intervention group
Group type: COMPARATOR
Intervention: Online evaluation
Number of subjects: 950
Study 34006080 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin
Number of subjects: 16
Study 34006080 — intervention group
Group type: COMPARATOR
Intervention: Bone graft material
Number of subjects: 16
Study 34006080 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone graft material and platelet-rich fibrin
Number of subjects: 16
Study 34081223 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiology-guided PCI using Fractional Flow Reserve (FFR)
Number of subjects: 0
Study 34081223 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hyperemic instantaneous wave-free ratio-guided revascularization
Number of subjects: 0
Study 34081223 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative flow reserve ratio assessment
Number of subjects: 0
Study 34081223 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary physiological assessment
Number of subjects: 0
Study 32210365 — intervention group
Group type: EXPERIMENTAL
Intervention: Vx-001
Number of subjects: 221
Study 32210365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 33370616 — intervention group
Group type: EXPERIMENTAL
Intervention: Water First intervention (installation of lead-free water stations, provision of cups/reusable water bottles, 6-month healthy beverage education campaign)
Number of subjects: 26
Study 33370616 — intervention group
Group type: EXPERIMENTAL
Intervention: Water First intervention
Number of subjects: 26
Study 32545038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepino extract 250mg/kg BW
Number of subjects: 20
Study 32545038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepino extract 500mg/kg BW
Number of subjects: 20
Study 32545038 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 34125321 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP with ERL and NDL
Number of subjects: 32
Study 34125321 — intervention group
Group type: COMPARATOR
Intervention: SRP with ultrasonic equipment and manual instruments (Control)
Number of subjects: 32
Study 36174917 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundle of care
Number of subjects: 260
Study 36174917 — intervention group
Group type: COMPARATOR
Intervention: Ordinary nursing care (control group)
Number of subjects: 260
Study 33184328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (100,000 IU single dose)
Number of subjects: 43
Study 33184328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 35735110 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 4 IVHVD
Number of subjects: 32
Study 35735110 — intervention group
Group type: COMPARATOR
Intervention: Grade 3 IVHVD
Number of subjects: 32
Study 35735110 — intervention group
Group type: EXPERIMENTAL
Intervention: Each extra vision impairment
Number of subjects: 32
Study 32006493 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of confidence intervals (CIs) in RCTs
Number of subjects: 102
Study 32006493 — intervention group
Group type: COMPARATOR
Intervention: Anesthesia/facial pain studies
Number of subjects: 102
Study 32006493 — intervention group
Group type: COMPARATOR
Intervention: Craniomaxillofacial deformities studies
Number of subjects: 102
Study 32006493 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reporting of P values
Number of subjects: 102
Study 34008107 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-side anastomosis
Number of subjects: 130
Study 34130339 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin for preventing preeclampsia and small-for-gestational-age births in high-risk women
Number of subjects: 0
Study 34130339 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin for secondary prevention of cardiovascular disease
Number of subjects: 0
Study 34130339 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin for recurrent venous thromboembolism
Number of subjects: 0